Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo

An ability to activate latent human immunodeficiency virus type 1 (HIV-1) expression could benefit many HIV cure strategies; however, most latency-reversing agents (LRAs) have proven disappointing. We evaluated AKT/mTOR activators as a potential new class of LRAs. Two glycogen synthase kinase-3 inhi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Virol
Hauptverfasser: Gramatica, Andrea, Schwarzer, Roland, Brantley, William, Varco-Merth, Benjamin, Sperber, Hannah S., Hull, Philip A., Montano, Mauricio, Migueles, Stephen A., Rosenthal, Danielle, Hogan, Louise E., Johnson, Jeffrey R., Packard, Thomas A., Grimmett, Zachary W., Herzig, Eytan, Besnard, Emilie, Nekorchuk, Michael, Hsiao, Feng, Deeks, Steven G., Snape, Michael, Kiernan, Bernard, Roan, Nadia R., Lifson, Jeffrey D., Estes, Jacob D., Picker, Louis J., Verdin, Eric, Krogan, Nevan J., Henrich, Timothy J., Connors, Mark, Ott, Melanie, Pillai, Satish K., Okoye, Afam A., Greene, Warner C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2021
Schlagworte:
Vaccines and Antiviral Agents
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8103695/
https://ncbi.nlm.nih.gov/pubmed/33536176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02393-20
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge